Company Overview and News
7h investorplace - 4
Now that the biotechnology sector is well on its way to bouncing back after bottoming in May 2018, investors may feel like they missed out. The fears that previously plagued biotech stocks are no longer as big a threat. The government is no longer putting companies hiking drug price in their cross-hairs, at least not for now. This favorable environment should help biotech firms carry out their plans for the rest of the year.
NKTR OPK EXEL CELGZ GERN JNJ CELG FOLD ALNY
It wasn’t a screaming bullish finish to the week, but it didn’t matter. The S&P 500’s 0.03% gain on Friday translated into a 1.1% advance for the five-day span. The close of 2,904.98 was the second-best close ever.
PCG OPK AMD ORCL WY
2018-09-14 globenewswire - 1
NEW YORK, Sept. 14, 2018 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading in OPKO Health, Inc. (Nasdaq: OPK) is scheduled to resume today, Friday, September 14, 2018, at 13:15:00 p.m. Eastern Time. Trading in the company’s stock was halted on September 7, 2018 at 14:34:38 p.m. Eastern Time.
Share price of Foamix Pharmaceuticals (FOMX) had a 54.4% spike on September 11 after-hours on the news of positive topline results of third Phase 3 clinical trial of its FMX101 drug. The candidate is indicated in the treatment of moderate-to-severe acne. The trial is reported to have successfully met both primary and secondary endpoints.
MKGAF OPK GILD INCY KMPH GLPG ACRX IMNP MKGAY NVS ABBV FMI PFE ABBV FOMX
2018-09-10 seekingalpha - 1
Discussion: First patient is dosed in Phase 1 clinical trial of Compugen's (CGEN)COM701 indicated as a cancer immunotherapy antibody targeting PVRIG. The safety and tolerability of the drug will be tested in escalating dose of COM701 as both monotherapy and combination therapy in a patient group of 140 with advanced solid tumors. The combination therapy will be administered along with a PD-1 inhibitor.
AZN AMGN OPK TEVJF GILD AZN JNJ CGEN TEVA TEVVF SRPT
OPKO Health and Immune Pharmaceuticals have denied any wrongdoing as the U.S. Securities and Exchange Commission (SEC) has charged current and former principals of the companies among 10 individuals with participating in transactions that generated $27 million from unlawful stock sales to smaller investors whose shares became virtually worthless. [Source: istock/csreed]
RIOT OPK IMNP BIOP
2018-09-07 nzherald.co.nz - 1
MIAMI (AP) — A Miami biotech billionaire with his name on the city's science museum has been charged in a market-manipulation scheme.
2018-09-07 marketwatch - 2
Billionaire and notable health-care investor Phillip Frost was one of 10 individuals and 10 associated firms charged by the Securities and Exchange Commission on Friday with participating in extremely profitable, yearslong pump-and-dump schemes.
OPK TEVJF TEVA TEVVF COCP
2017-10-16 - Asif
Opko Health is a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Its diagnostics business includes BioReference Laboratories (“BioReference”), the nation’s third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform (in development). Opko Health's pharmaceutical business features Rayaldee , an FDA-approved treatment for secondary hyperparathyroidism (“SHPT”) in adults with stage 3 or 4 chronic kidney disease (“CKD”) and vitamin D insufficiency (launched in November 2016), and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO in November 2015 and pending approval for IV formulation), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clini...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to OPK / Opko Health, Inc. on message board site Silicon Investor.
as of ET